Press release
Non-Small Cell Lung Cancer Clinical Trial Pipeline Analysis: 100+ Key Companies Shaping the Future of NSCLC Therapeutics | DelveInsight
DelveInsight's Non-Small Cell Lung Cancer (NSCLC) Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline NSCLC therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the NSCLC pipeline domain.Key takeaways from the NSCLC Clinical Trial Landscape Report
• DelveInsight's NSCLC pipeline report depicts a robust space with 100+ active players working to develop 120+ pipeline therapies for NSCLC treatment.
• Key NSCLC companies such as Cullinan Therapeutics, Taiho Pharmaceuticals, Zumutor Biologics, Maia Biotechnology, Sichuan Baili Pharmaceutical, Adaptimmune, Janux Therapeutics, ORIC Pharmaceuticals, Jazz Pharmaceuticals, Gilead Sciences, and others
• Promising NSCLC pipeline therapies in various stages of development include Zipalertinib, Zimberelimab, Zanidatamab, JANX008, and others
Request a sample and discover the recent advances in NSCLC treatment drugs at: https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
What is Non-Small Cell Lung Cancer (NSCLC)?
Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. It is characterized by uncontrolled growth of abnormal cells in the lung tissues and may spread to lymph nodes and distant organs as the disease progresses. The symptoms include persistent cough, chest pain, shortness of breath, coughing up blood, fatigue, and weight loss. The treatment involves surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. The causes are associated with tobacco smoking, environmental exposures, and genetic factors. The diagnosis is based on imaging techniques such as CT, PET, or MRI scans followed by biopsy and molecular testing.
Emerging NSCLC Drug Profiles
Zipalertinib: Cullinan Therapeutics / Taiho Pharmaceuticals
Zipalertinib (CLN-081/TAS6417) is an orally available small molecule designed to target activating mutations in EGFR. Its active mechanism enables inhibition of EGFR variants with exon 20 insertion mutations while sparing wild-type EGFR. The therapy is designed as a next generation irreversible EGFR inhibitor for the treatment of genetically defined NSCLC patients. The therapy has received Breakthrough Therapy Designation in the United States for its development in non-small cell lung cancer and is currently in Phase III clinical development.
Zimberelimab: Gilead Sciences
Zimberelimab is a monoclonal antibody being developed for multiple oncology indications, including Non-Small Cell Lung Cancer (NSCLC). It targets programmed cell death receptor pathways and is administered intravenously. The therapy is currently in Phase III clinical development and is being evaluated for its role in treating NSCLC and other solid tumors.
Learn more about the novel and emerging NSCLC pipeline therapies at: https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
Recent Developments in the NSCLC Clinical Trial Landscape
• In November 2025, Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. announced that the companies have initiated a New Drug Application (NDA) submission for zipalertinib for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC).
• In September 2025, Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. announced continued clinical progress of zipalertinib in patients with NSCLC, highlighting encouraging efficacy signals in ongoing studies.
• In August 2025, systImmune Inc. and Bristol Myers Squibb announced that findings from recent developments with izalontamab brengitecan in the treatment of Non-Small Cell Lung Cancer (NSCLC) have received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA).
• In June 2025, Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. announced ongoing clinical development activities for their NSCLC pipeline candidates, focusing on advancing targeted therapies across early and mid-stage trials.
Scope of the NSCLC Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Parenteral, Topical, Intratumoural
• Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Polymer, Peptide, Gene Therapy
• Key NSCLC Companies: Cullinan Therapeutics, Taiho Pharmaceuticals, Maia Biotechnology, Janux Therapeutics, Adaptimmune, and others
• Key NSCLC Pipeline Therapies: Zipalertinib, Zimberelimab, Zanidatamab, JANX008, and others
Dive deep into rich insights for new drugs for NSCLC treatment, visit https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
Table of Contents
1. NSCLC Pipeline Report Introduction
2. NSCLC Pipeline Report Executive Summary
3. NSCLC Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. NSCLC Pipeline Therapeutics
6. NSCLC Pipeline: Late Stage Products (Pre-registration)
7. NSCLC Pipeline: Late Stage Products (Phase III)
8. NSCLC Pipeline: Mid Stage Products (Phase II)
9. NSCLC Pipeline: Early Stage Products (Phase I)
10. NSCLC Pipeline Therapeutics Assessment
11. Inactive Products in the NSCLC Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products in the NSCLC Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
For further information on the NSCLC pipeline therapeutics, reach out
https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-Small Cell Lung Cancer Clinical Trial Pipeline Analysis: 100+ Key Companies Shaping the Future of NSCLC Therapeutics | DelveInsight here
News-ID: 4502282 • Views: …
More Releases from DelveIinsight Business Research
The Global Protein Expression Market Size is estimated to grow at a CAGR of 7.67 …
DelveInsight's Protein Expression Market Insights Report 2032 provides the current and forecast market analysis, individual leading companies market shares, challenges, Market Drivers, barriers, trends, and key market Companies in the market.
To read more about the latest highlights related to the Protein Expression Market, get a snapshot of the key highlights entailed in the Market Report @ Protein Expression Market Size- https://www.delveinsight.com/sample-request/protein-expression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Protein Expression Market Report
• In June 2024,…
Severe Asthma Clinical Trial Pipeline Analysis: 30+ Key Companies Shaping the Fu …
DelveInsight's Severe Asthma Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Severe Asthma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Severe Asthma pipeline domain.
Key takeaways from the Severe Asthma Clinical Trial Landscape Report
• DelveInsight's Severe Asthma pipeline report depicts a robust space with 30+ active players working to develop 30+…
Acute Respiratory Distress Syndrome Clinical Trial Pipeline Analysis: 40+ Key Co …
DelveInsight's Acute Respiratory Distress Syndrome (ARDS) Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Acute Respiratory Distress Syndrome (ARDS) therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Acute Respiratory Distress Syndrome (ARDS) pipeline domain.
Key takeaways from the Acute Respiratory Distress Syndrome (ARDS) Clinical Trial Landscape Report
• DelveInsight's Acute Respiratory Distress Syndrome…
Systemic Lupus Erythematosus Clinical Trial Pipeline Analysis: 120+ Key Companie …
DelveInsight's Systemic Lupus Erythematosus (SLE) Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline SLE therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the SLE pipeline domain.
Key takeaways from the SLE Clinical Trial Landscape Report
• DelveInsight's SLE pipeline report depicts a robust space with 120+ active players working to develop 140+ pipeline therapies…
More Releases for NSCLC
NSCLC Treatment Market to Reach USD 55.30B by 2035
Non-Small Cell Lung Cancer Treatment Market: Growth Drivers, Innovation, and the Future of Lung Cancer Care
The Non-Small Cell Lung Cancer (NSCLC) Treatment Market is undergoing a profound transformation as advances in diagnostics, targeted therapies, and immuno-oncology redefine how lung cancer is managed globally. NSCLC accounts for nearly 85% of all lung cancer cases, making it the most prevalent and commercially significant segment of the lung cancer therapeutics market.
Historically, NSCLC was…
NSCLC Patient Insights You Can't Afford to Ignore! A DelveInsight Case Study - H …
DelveInsight, a global leader in healthcare market intelligence and consulting, has successfully partnered with a top-tier biopharmaceutical company specializing in oncology to provide an advanced epidemiology forecasting analysis of Non-Small Cell Lung Cancer (NSCLC). This comprehensive study focused on biomarker-specific segmentation to support strategic drug development, identify target patient populations, and optimize market access planning across global markets.
With the increasing complexity of NSCLC treatment, biomarker-driven therapies have emerged as a…
Huateng Pharma Supplies Intermeidates of Pemetrexed Against NSCLC
Pemetrexed disodium is a drug successfully developed by Eli Lilly in the United States for the treatment of tumors, patent protection to January 2017. Pemetrexed disodium is a multi-targeted anti-folate agent with a core pyrrolopyrimidine moiety in its structure. It is a dual inhibitor of nucleotide synthase/dihydrofolate reductase, which inhibits cell replication by disrupting the normal process of folate-dependent metabolism in cells and simultaneously blocking three different enzyme targets critical…
NSCLC Market Global Industry Analysis and Forecast Till 2027
Any type of epithelial lung cancer that isn't small cell lung cancer is referred to as NSCLC (SCLC). Squamous cell carcinoma, large cell carcinoma, and adenocarcinoma are the most common kinds of NSCLC, although there are several more types that are less common, and all types can occur in atypical histologic variants.
Request Sample Copy of this Report: https://www.infinitybusinessinsights.com/request_sample.php?id=562904
Top Key Players Included in This Report: Merck KGa, Roche, Nlyte, Taxotere,…
Targeted Drugs for NSCLC Market Size by 2025: QY Research
Global Targeted Drugs for NSCLC market report is first of its kind research report that covers the overview, summary, market dynamics, competitive analysis, and leading player’s various strategies to sustain in the global market. This report covers five top regions of the globe and countries within, which shows the status of regional development, consisting of market value, volume, size, and price data. Apart from this, the report also covers detail…
"NSCLC - Market Outlook and Competitive Landscape Report 2015 – 2030 "
Report Snapshot:
NSCLC is the most common form of lung cancer, accounting for approximately 85% of all types and subtypes of lung cancer. It grows and spreads more slowly than small cell lung cancer. Early stage disease is associated with uncommon specific symptoms; hence roughly ~50% to 73% of cases are not being diagnosed until the disease is at an advanced stage when the chances for cure or significant patient benefit…
